Target Engagement and Cognitive Outcomes of Anti‐Amyloid Immunotherapies in Early‐Onset Alzheimer's Disease: First Report from the LEADS Study

We observed excellent target engagement, with piecewise regression models showing rates of Aβ clearance comparable to those seen in Phase 3 trials. The study was underpowered to detect cognitive benefits, which are limited over a short follow-up interval. These findings underscore the utility of observational studies with biomarker data in evaluating treatment efficacy, offering insights that complement traditional randomized trials.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_104661
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Target Engagement and Cognitive Outcomes of Anti‐Amyloid Immunotherapies in Early‐Onset Alzheimer's Disease: First Report from the LEADS Study

Ganna Blazhenets, Marı́a C. Carrillo, Piyush Maiti, Konstantinos Chiotis et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Target Engagement and Cognitive Outcomes of Anti‐Amyloid Immunotherapies in Early‐Onset Alzheimer's Disease: First Report from the LEADS Study

Ganna Blazhenets, Marı́a C. Carrillo, Piyush Maiti, Konstantinos Chiotis, Liana G. Apostolova, Ani Eloyan, Jiaxiuxiu Zhang, Kala Kirby, Gil D. Rabinovici, Alexandra Touroutoglou, Brad C. Dickerson
article en

Abstract

We observed excellent target engagement, with piecewise regression models showing rates of Aβ clearance comparable to those seen in Phase 3 trials. The study was underpowered to detect cognitive benefits, which are limited over a short follow-up interval. These findings underscore the utility of observational studies with biomarker data in evaluating treatment efficacy, offering insights that complement traditional randomized trials.

Alzheimer s & DementiaVol. 21(S2)
Alzheimer's Association (US), University of California, San Francisco (US), Brown University (US), University of California System (US), Massachusetts General Hospital (US), University Memory and Aging Center (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)
Openalex Percentile: Top 31%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.